Amneal Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Amneal Pharmaceuticals, Inc. en bref

Amneal Pharmaceuticals, Inc. (AMRX) is currently trading at 14,13 € with a market capitalization of 4,5 Md €. The trailing P/E ratio stands at 43.81x, with a forward P/E of 14.43x. The 52-week range spans from 6,69 € to 14,48 €; the current price is 2.4% below the yearly high. Year-over-year revenue growth stands at +3.9%. The net profit margin stands at 4.01%.

💰 Dividende

Amneal Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

4 analystes évaluent Amneal Pharmaceuticals, Inc. (AMRX) au consensus : Achat Fort. L'objectif de cours moyen est de 15,04 €, soit un potentiel de +6.42% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,95 € à 16,56 €.

Amneal Pharmaceuticals, Inc. : la thèse d'investissement en détail

Amneal Pharmaceuticals, Inc. (AMRX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 384.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

Le scénario baissier

Revenue growth has slowed to just 3.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 4.01%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. The debt-to-equity ratio of 6750.84% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The forward P/E of 14.43x is meaningfully below the trailing 43.81x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 95.5% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Amneal Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.